Skip to content

Francisco Silveira Guimarães

6 papers in the library · 1,231 citations · publishing 2006-2026

Papers

Sort Most recent Most cited

Sex-specific role of microglia in Δ9-tetrahydrocannabinol-induced disruption of fear memory reconsolidation.

Neuropsychopharmacology May 9, 2026 Ana Maria Raymundi, Nathalie Carla Cardoso, Gabriel Costa Lourenço et al.

In PTSD, microglia are more engaged in fear-related circuits, where they participate in fear memory processing responses. The reconsolidation-impairing effect of Δ⁹-tetrahydrocannabinol (THC), the primary psychoactive constituent of Cannabis, is typically linked to cannabinoid type-1 receptor (CB1) signaling. THC also engages peroxisome proliferator-activated receptor gamma (PPARγ), and both...

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age

Frontiers in Immunology September 21, 2018 José A. Crippa, Francisco Silveira Guimarães, Alline Cristina Campos et al. 312 citations

Background: Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. Objectives: The aim of the present review is to describe the main advances in the development of the experimental and clinical use of cannabidiol CBD in neuropsychiatry. Methods: A non-systematic search was performed for studies...

Plastic and Neuroprotective Mechanisms Involved in the Therapeutic Effects of Cannabidiol in Psychiatric Disorders

Frontiers in Pharmacology May 23, 2017 Alline Cristina Campos, Manoela V. Fogaça, Franciele Franco Scarante et al. 176 citations

Beneficial effects of cannabidiol (CBD) have been described for a wide range of psychiatric disorders, including anxiety, psychosis, and depression. The mechanisms responsible for these effects, however, are still poorly understood. Similar to clinical antidepressant or atypical antipsychotic drugs, recent findings clearly indicate that CBD, either acutely or repeatedly administered, induces...

Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life

Frontiers in Pharmacology May 11, 2017 Antônio Waldo Zuardi, Natália Pegoraro Rodrigues, Angélica L. Silva et al. 292 citations

The purpose of this study was to investigate whether the anxiolytic effect of cannabidiol (CBD) in humans follows the same pattern of an inverted U-shaped dose-effect curve observed in many animal studies. Sixty healthy subjects of both sexes aged between 18 and 35 years were randomly assigned to five groups that received placebo, clonazepam (1 mg), and CBD (100, 300, and 900 mg). The subjects...

Effects of nitric oxide-related compounds in the acute ketamine animal model of schizophrenia

BMC Neuroscience March 5, 2015 Ludmyla Kandratavicius, Priscila Alves Balista, Daniele C. Wolf et al. 40 citations

BACKGROUND: Better treatments for schizophrenia are urgently needed. The therapeutic use of the nitric oxide (NO)-donor sodium nitroprusside (SNP) in patients with schizophrenia has shown promising results. The role of NO in schizophrenia is still unclear, and NO modulation is unexplored in ketamine (KET) animal models to date. In the present study, we compared the behavioral effects of pre-...

DOI: 10.1186/s12868-015-0149-3 (opens in new tab) Ketamine Schizophrenia object-oriented programming Sodium nitroprusside Therapeutic effect +6

Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug

Brazilian Journal of Medical and Biological Research April 1, 2006 Antônio Waldo Zuardi, José A. Crippa, Jaime E. C. Hallak et al. 411 citations

A high dose of delta9-tetrahydrocannabinol, the main Cannabis sativa (cannabis) component, induces anxiety and psychotic-like symptoms in healthy volunteers. These effects of delta9-tetrahydrocannabinol are significantly reduced by cannabidiol (CBD), a cannabis constituent which is devoid of the typical effects of the plant. This observation led us to suspect that CBD could have anxiolytic...